Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA's new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications.

Lawrence X Yu1, Andre Raw1, Larisa Wu1

  • 1Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, United States.

International Journal of Pharmaceutics: X
|September 14, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products.

Journal of pharmaceutical sciences·2026
Same author

Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets.

International journal of pharmaceutics·2024
Same author

Antioxidants had No Effects on the In-Vitro Permeability of BCS III Model Drug Substances.

Journal of pharmaceutical sciences·2024
Same author

Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters.

Pharmaceutics·2024
Same author

A network of regulatory innovations to improve FDA quality assessments of human drug applications.

International journal of pharmaceutics: X·2024
Same author

Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.

Journal of pharmaceutical sciences·2023

The FDA

Area of Science:

  • Pharmaceutical quality assessment
  • Regulatory science
  • Drug lifecycle management

Background:

  • Current pharmaceutical quality assessment relies on text-based narratives.
  • Need for standardized, efficient, and consistent regulatory oversight.
  • Importance of drug quality for safety and efficacy.

Purpose of the Study:

  • Introduce the Knowledge-aided Assessment & Structured Application (KASA) system.
  • Describe KASA's design for capturing knowledge and performing risk assessments.
  • Highlight KASA's role in advancing pharmaceutical quality.

Main Methods:

  • Knowledge capture and management throughout the drug product lifecycle.
  • Development of rules and algorithms for risk assessment and control.
Keywords:
Knowledge managementPharmaceutical qualityRisk assessmentRisk controlStructured application

Related Experiment Videos

  • Computer-aided analysis of applications for regulatory standard comparison.
  • Structured assessment minimizing text-based summarization.

    • Main Results:

    • KASA system designed for comprehensive pharmaceutical quality assessment.
    • Enables computer-aided analysis and structured regulatory review.
    • Facilitates lifecycle management of drug products and facilities.

    Conclusions:

    • KASA enhances effectiveness, efficiency, and consistency in regulatory quality oversight.
    • Standardized information sharing improves regulatory processes.
    • KASA advances the FDA's focus on pharmaceutical quality, ensuring drug safety and efficacy.